Atea Pharmaceuticals, Inc.
AVIR
$4.49
$0.143.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -169.52M | -158.35M | -147.03M | -136.13M | -139.49M |
| Total Depreciation and Amortization | 416.00K | 416.00K | 416.00K | 416.00K | 416.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.36M | 9.42M | 23.58M | 29.71M | 36.06M |
| Change in Net Operating Assets | 13.89M | 16.48M | -11.18M | -10.86M | -23.18M |
| Cash from Operations | -147.86M | -132.03M | -134.21M | -116.87M | -126.20M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 132.92M | 188.79M | 138.83M | -24.49M | 84.91M |
| Cash from Investing | 132.92M | 188.79M | 138.83M | -24.49M | 84.91M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.12M | 259.00K | 259.00K | 255.00K | 255.00K |
| Repurchase of Common Stock | -26.27M | -26.00M | -26.00M | -14.58M | -485.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -25.14M | -25.75M | -25.75M | -14.32M | -230.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -40.08M | 31.02M | -21.12M | -155.67M | -41.52M |